Demin Jr O, Yakovleva T, Kolobkov D and Demin O. Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model. 2014 Front. Pharmacol. 5, 218.
Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH. A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain. 2014 CPT Pharmacometrics Syst Pharmacol. 3, e91.
Smirnov S., Metelkin E., Gizzatkulov N., Stepanov O., Demin O. "Towards Modeling of Metabolic Syndrome: Tissue Crosstalk in Lipid Spillover" in "A Systems Biology Approach to Study Metabolic Syndrome" Springer 2014 p.341.
Demin O, Karelina T, Svetlichniy D, Metelkin E, Speshilov G, Demin O Jr, Fairman D, van der Graaf PH, Agoram BM. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. 2013 CPT Pharmacometrics Syst Pharmacol. 2, e74.
Benson N., Matsuura T., Smirnov S., Demin O., Jones HM., Dua P., van der Graaf PH. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. 2013 Interface Focus 3: 20120071.
Demin OO, Smirnov SV, Sokolov VV, Cucurull-Sanchez L, Pichardo-Almarza C, Flores MV, Benson N, Demin OV. Modeling of celiac disease immune response and the therapeutic effect of potential drugs. 2013 BMC Syst Biol. 56.
Thank you for your message! We will get back to you shortly.
First
Prev